Literature DB >> 14717972

Formation of tissue factor-factor VIIa-factor Xa complex promotes cellular signaling and migration of human breast cancer cells.

X Jiang1, M A Bailly, T S Panetti, M Cappello, W H Konigsberg, M E Bromberg.   

Abstract

Tissue factor (TF) is a transmembrane glycoprotein that initiates blood coagulation when complexed with factor (F)VIIa. Recently, TF has been shown to promote cellular signaling, tumor growth, angiogenesis, and metastasis. In the present study, we examined the pathway by which TF-FVIIa complex induces cellular signaling in human breast cancer cells using the Adr-MCF-7 cell line. This cell line has high endogenous TF expression as measured by flow cytometry and expression of protease-activated receptors 1 and 2 (PAR1 and PAR2) as determined by reverse transcriptase-polymerase chain reaction analysis. Both PAR1 and PAR2 are functionally active as determined by induction of p44/42 mitogen-activated protein kinase (MAPK) phosphorylation using specific agonist peptides. We found that MAPK phosphorylation in this cell line was strongly induced by the combination of FVIIa and factor (F)X, but not by FVIIa alone at a concentration of FVIIa that approaches physiological levels. Induction of MAPK phosphorylation involved the formation of TF-FVIIa-FXa complex and occurred by a pathway that did not require thrombin formation, indicating a critical role for FXa generation. In addition, induction of MAPK phosphorylation was found to be independent of PAR1 activation. We then examined whether TF-FVIIa complex formation could promote tumor cell migration using a modified Boyden chamber chemotaxis assay. The combination of FVIIa and FX, but not FVIIa alone, strongly induced migration of tumor cells by a pathway that probably involves PAR2, but not PAR1 activation. MAPK phosphorylation was found to be required for the induction of cell migration by the combination of FVIIa and FX. These data suggest that TF-FVIIa-mediated signaling in human breast cancer cells occurs most efficiently by formation of the TF-FVIIa-FXa complex. One of the physiological consequences of this signaling pathway is enhanced cell migration that is probably mediated by PAR2, but not PAR1 activation.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14717972     DOI: 10.1111/j.1538-7836.2004.00545.x

Source DB:  PubMed          Journal:  J Thromb Haemost        ISSN: 1538-7836            Impact factor:   5.824


  29 in total

Review 1.  Protease-activated receptor 2 signaling in inflammation.

Authors:  Andrea S Rothmeier; Wolfram Ruf
Journal:  Semin Immunopathol       Date:  2011-10-06       Impact factor: 9.623

Review 2.  Tumor vascular infarction: prospects and challenges.

Authors:  Rana Jahanban-Esfahlan; Khaled Seidi; Nosratollah Zarghami
Journal:  Int J Hematol       Date:  2017-01-02       Impact factor: 2.490

Review 3.  Tissue factor and PAR2 signaling in the tumor microenvironment.

Authors:  Florence Schaffner; Wolfram Ruf
Journal:  Arterioscler Thromb Vasc Biol       Date:  2009-08-06       Impact factor: 8.311

4.  MicroRNA-19 (miR-19) regulates tissue factor expression in breast cancer cells.

Authors:  Xiaoxi Zhang; Haijun Yu; Jessica R Lou; Jie Zheng; Hua Zhu; Narcis-Ioan Popescu; Florea Lupu; Stuart E Lind; Wei-Qun Ding
Journal:  J Biol Chem       Date:  2010-11-08       Impact factor: 5.157

5.  Hepatocyte nuclear factor-4-independent synthesis of coagulation factor VII in breast cancer cells and its inhibition by targeting selective histone acetyltransferases.

Authors:  Shiro Koizume; Naho Yokota; Etsuko Miyagi; Fumiki Hirahara; Yoshiyasu Nakamura; Yuji Sakuma; Akira Yoshida; Yoichi Kameda; Eiju Tsuchiya; Wolfram Ruf; Yohei Miyagi
Journal:  Mol Cancer Res       Date:  2009-12-08       Impact factor: 5.852

6.  Protease-activated receptors mediate crosstalk between coagulation and fibrinolysis.

Authors:  Troy A McEachron; Rafal Pawlinski; Kristy L Richards; Frank C Church; Nigel Mackman
Journal:  Blood       Date:  2010-08-24       Impact factor: 22.113

7.  Thrombin Signaling Promotes Pancreatic Adenocarcinoma through PAR-1-Dependent Immune Evasion.

Authors:  Yi Yang; Amanda Stang; Patrick G Schweickert; Nadia A Lanman; Erin N Paul; Brett P Monia; Alexey S Revenko; Joseph S Palumbo; Eric S Mullins; Bennett D Elzey; Edith M Janssen; Stephen F Konieczny; Matthew J Flick
Journal:  Cancer Res       Date:  2019-05-02       Impact factor: 12.701

Review 8.  Breast cancer phenotypes regulated by tissue factor-factor VII pathway: Possible therapeutic targets.

Authors:  Shiro Koizume; Yohei Miyagi
Journal:  World J Clin Oncol       Date:  2014-12-10

9.  Tissue factor as a novel target for treatment of breast cancer.

Authors:  Marion Cole; Michael Bromberg
Journal:  Oncologist       Date:  2013-01-03

10.  Angiogenesis is associated with the onset of hyperplasia in human ductal breast disease.

Authors:  J E Bluff; S R Menakuru; S S Cross; S E Higham; S P Balasubramanian; N J Brown; M W Reed; C A Staton
Journal:  Br J Cancer       Date:  2009-07-21       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.